Novartis ups guidance again as generic Diovan stays at bay
This article was originally published in Scrip
Executive Summary
Novartis no longer expects a generic version of its blockbuster antihypertensive Diovan (valsartan) to be launched in the US before the end of the year, and has upped its financial guidance accordingly.